Andreas Pinter, Ahmed M. Soliman, Karina C. Manz, Valeria Weber, Paul Ludwig, Anja Mocek, Ariane Höer, Mark G. Lebwohl
{"title":"斑块型银屑病患者接受生物制剂治疗的治疗转换和相关经济结果：2016 - 2021年德国索赔数据的回顾性分析","authors":"Andreas Pinter, Ahmed M. Soliman, Karina C. Manz, Valeria Weber, Paul Ludwig, Anja Mocek, Ariane Höer, Mark G. Lebwohl","doi":"10.1002/jvc2.512","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Biologics are therapeutic options for the management of moderate−severe plaque psoriasis. Some patients need to switch biologic treatment to achieve satisfactory outcomes, which might have a considerable economic impact.</p>\n </section>\n \n <section>\n \n <h3> Objectives</h3>\n \n <p>We assessed the characteristics and switch rates of patients with plaque psoriasis initiating biologic treatment and compared healthcare resource utilization (HCRU) and associated costs for switching and non-switching.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This study was a retrospective claims-based analysis comprising a 182-day baseline period to identify patient characteristics and a 365-day follow-up to assess switch rates, HCRU and associated costs. Data covering claims activity from 2016 to 2021 in a representative sample of four million individuals with statutory insurance in Germany was used.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>We identified 2565 patients with psoriasis initiating biologic treatment with anti-IL-17 (<i>n</i> = 1037), anti-IL-23 (<i>n</i> = 704), anti-TNF-α (<i>n</i> = 583) and anti-IL-12/23 (<i>n</i> = 241) agents. A total of 9.2% of patients switched therapy to another biologic during follow-up, ranging from 4.9% (secukinumab) to 16.5% (etanercept). The probability of treatment switching was significantly lower in patients treated with risankizumab (<i>p</i> < 0.05) than in patients treated with other biologics except guselkumab (<i>p</i> = 0.14). HCRU and associated costs during the follow-up were generally higher with a therapy switch (all-cause: 32,263 ± 15,381€) than without (25,041 ± 12,090€). This applied to direct costs (outpatient services, hospitalization, drug treatment) and indirect costs (sickness benefits). Drug treatment accounted for the largest share of costs.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Treatment switching is frequent in patients with moderate−severe plaque psoriasis initiating biologic therapy and is associated with increased HCRU and associated costs. As the probability that a switch occurs within 365 days after treatment initiation widely differs between biologic agents, further research is warranted to determine the underlying reasons for switching to help establish clinically and economically sound therapy sequences.</p>\n </section>\n </div>","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"3 5","pages":"1537-1547"},"PeriodicalIF":0.0000,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.512","citationCount":"0","resultStr":"{\"title\":\"Treatment switching and associated economic outcomes in patients with plaque psoriasis treated with biologics: A retrospective analysis of German claims data 2016−2021\",\"authors\":\"Andreas Pinter, Ahmed M. Soliman, Karina C. Manz, Valeria Weber, Paul Ludwig, Anja Mocek, Ariane Höer, Mark G. Lebwohl\",\"doi\":\"10.1002/jvc2.512\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>Biologics are therapeutic options for the management of moderate−severe plaque psoriasis. Some patients need to switch biologic treatment to achieve satisfactory outcomes, which might have a considerable economic impact.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Objectives</h3>\\n \\n <p>We assessed the characteristics and switch rates of patients with plaque psoriasis initiating biologic treatment and compared healthcare resource utilization (HCRU) and associated costs for switching and non-switching.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>This study was a retrospective claims-based analysis comprising a 182-day baseline period to identify patient characteristics and a 365-day follow-up to assess switch rates, HCRU and associated costs. Data covering claims activity from 2016 to 2021 in a representative sample of four million individuals with statutory insurance in Germany was used.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>We identified 2565 patients with psoriasis initiating biologic treatment with anti-IL-17 (<i>n</i> = 1037), anti-IL-23 (<i>n</i> = 704), anti-TNF-α (<i>n</i> = 583) and anti-IL-12/23 (<i>n</i> = 241) agents. A total of 9.2% of patients switched therapy to another biologic during follow-up, ranging from 4.9% (secukinumab) to 16.5% (etanercept). The probability of treatment switching was significantly lower in patients treated with risankizumab (<i>p</i> < 0.05) than in patients treated with other biologics except guselkumab (<i>p</i> = 0.14). HCRU and associated costs during the follow-up were generally higher with a therapy switch (all-cause: 32,263 ± 15,381€) than without (25,041 ± 12,090€). This applied to direct costs (outpatient services, hospitalization, drug treatment) and indirect costs (sickness benefits). Drug treatment accounted for the largest share of costs.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>Treatment switching is frequent in patients with moderate−severe plaque psoriasis initiating biologic therapy and is associated with increased HCRU and associated costs. As the probability that a switch occurs within 365 days after treatment initiation widely differs between biologic agents, further research is warranted to determine the underlying reasons for switching to help establish clinically and economically sound therapy sequences.</p>\\n </section>\\n </div>\",\"PeriodicalId\":94325,\"journal\":{\"name\":\"JEADV clinical practice\",\"volume\":\"3 5\",\"pages\":\"1537-1547\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-08-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.512\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JEADV clinical practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/jvc2.512\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JEADV clinical practice","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jvc2.512","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Treatment switching and associated economic outcomes in patients with plaque psoriasis treated with biologics: A retrospective analysis of German claims data 2016−2021
Background
Biologics are therapeutic options for the management of moderate−severe plaque psoriasis. Some patients need to switch biologic treatment to achieve satisfactory outcomes, which might have a considerable economic impact.
Objectives
We assessed the characteristics and switch rates of patients with plaque psoriasis initiating biologic treatment and compared healthcare resource utilization (HCRU) and associated costs for switching and non-switching.
Methods
This study was a retrospective claims-based analysis comprising a 182-day baseline period to identify patient characteristics and a 365-day follow-up to assess switch rates, HCRU and associated costs. Data covering claims activity from 2016 to 2021 in a representative sample of four million individuals with statutory insurance in Germany was used.
Results
We identified 2565 patients with psoriasis initiating biologic treatment with anti-IL-17 (n = 1037), anti-IL-23 (n = 704), anti-TNF-α (n = 583) and anti-IL-12/23 (n = 241) agents. A total of 9.2% of patients switched therapy to another biologic during follow-up, ranging from 4.9% (secukinumab) to 16.5% (etanercept). The probability of treatment switching was significantly lower in patients treated with risankizumab (p < 0.05) than in patients treated with other biologics except guselkumab (p = 0.14). HCRU and associated costs during the follow-up were generally higher with a therapy switch (all-cause: 32,263 ± 15,381€) than without (25,041 ± 12,090€). This applied to direct costs (outpatient services, hospitalization, drug treatment) and indirect costs (sickness benefits). Drug treatment accounted for the largest share of costs.
Conclusions
Treatment switching is frequent in patients with moderate−severe plaque psoriasis initiating biologic therapy and is associated with increased HCRU and associated costs. As the probability that a switch occurs within 365 days after treatment initiation widely differs between biologic agents, further research is warranted to determine the underlying reasons for switching to help establish clinically and economically sound therapy sequences.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
